Università Degli Studi Di Camerino

Curelab Oncology, Inc.

Antonio Concetti

Franco Venanzi

Michael Sherman

Augusto Amici

Alexander Shneider

Vladimir Gabai

Victor Shifrin

Dimitrios Agas

Maria Giovanna Sabbieti

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.

Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases

Polynucleotide immunogenic agents capable of inducing an immune response towards the members of the Epidermal Growth Factor Receptors (EGFR) family are disclosed.

Polynucleotide immunogenic agents

Growing community of inventors

Falerone, Italy

Antonio Concetti